FIELD: medicine, oncology. SUBSTANCE: proposed agent is hexapeptide of the formula Leu-Val-Val-Tyr-Pro-Trp that is used as antitumor agent. Indicated hexapeptide shows expressed cytostatic effect, inhibits the proliferation of different tumors (lympholeukosis P-388, melanoma B-16). This hexapeptide is able to recover T-lymphocyte function depressed by tumor action that are important the main role in antitumor protection. Hexapeptide is not toxic and can be used for treatment of broad spectrum oncologic diseases. EFFECT: high effectiveness of agent. 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HEXAPEPTIDE (BIVALFOR) SHOWING ANTITUMOR ACTIVITY | 1993 |
|
RU2064935C1 |
| IMMUNOMODULATOR WITH ANTITUMOR ACTIVITY AND DRUG BASED ON THE SAME | 2005 |
|
RU2283663C1 |
| AGENT "SERAMIL" FOR TREATMENT OF SICKNESS OF BACTERIAL NATURE | 2002 |
|
RU2210383C1 |
| PEPTIDE-IMMUNOREGULATOR (VERSIONS), MEDICINAL AGENT COMPRISING PEPTIDE-IMMUNOREGULATOR | 1998 |
|
RU2198178C2 |
| ANTITUMOR AGENT AND A METHOD OF ITS EVALUATION | 2019 |
|
RU2803148C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| AGENT REDUCING RELATIVE CONTENT OF LOW-DIFFERENTIATED CELLS AND INCREASING RELATIVE CONTENT OF HIGH-DIFFERENTIATED CELLS IN INVASIVE MAMMARY GLAND CARCINOMA OF NON-SPECIFIC TYPE | 2022 |
|
RU2786528C1 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| PEPTIDE WITH ANTIPROLIFERATIVE ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR TREATING PROLIFERATIVE DISEASES | 2007 |
|
RU2446174C2 |
| MESOTHELINIC CAR RECEPTORS AND USE THEREOF | 2020 |
|
RU2822193C2 |
